Completed PHASE3 INTERVENTIONAL 2-arm NCT00194519

Herpes Simplex Virus Type 2 (HSV-2) Suppression to Prevent HIV Transmission

Phase III Randomized Placebo-Controlled Trial of HSV-2 Suppression to Prevent HIV Transmission Among HIV-Discordant Couples

Sponsor: Bill and Melinda Gates Foundation

Conditions HIV Infection Herpes Simplex, Genital Sexually Transmitted Diseases

Interventions Generic acyclovir Placebo

Updated 6 times since 2017 Last updated: Oct 9, 2018 Started: Nov 30, 2004 Primary completion: Nov 30, 2009 Completion: Mar 31, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00194519, this PHASE3 trial focuses on HIV Infection and Herpes Simplex, Genital and remains completed. Sponsored by Bill and Melinda Gates Foundation, it has been updated 6 times since 2004, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Nov 2018 — Jan 2021 [monthly]

Completed PHASE3
Jun 2018 — Nov 2018 [monthly]

Completed PHASE3

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Nov 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Bill and Melinda Gates Foundation
University of Washington

Data source: University of Washington

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Cape Town, South Africa , Eldoret, Kenya , Gabarone, Botswana , Johannesburg, South Africa , Kampala, Uganda , Kigali, Rwanda , Kisumu, Kenya , Lusaka, Zambia , Moshi, Tanzania , Nairobi, Kenya and 2 more locations